目的：探讨高强度超声聚焦刀联合FOLFOX4方案治疗晚期胰腺癌的疗效及安全性。方法60例晚期胰腺癌患者根据所采取的治疗方式分为治疗组32例和对照组28例，两组均行FOLFOX4方案化疗，治疗组联合高强度超声聚焦刀治疗。比较两组疗效、不良反应、疼痛缓解情况及无病生存时间（PFS）。结果6治疗组和对照组的有效率（RR）分别为28.1%和7.1%，疾病控制率（DCR）分别为71.9%和35.7%，治疗组高于对照组，差异有统计学意义（P﹤0.05）。治疗组的疼痛缓解率为53.1%（17/32），高于对照组的21.4%（6/28），差异有统计学意义（P﹤0.05）。治疗组的中位PFS为6.1个月，长于对照组的2.8个月，差异有统计学意义（P﹤0.05）。两组治疗最常见的不良反应为血液学毒性、恶心呕吐、神经毒性，但两组比较差异均无统计学意义（P﹥0.05）。结论高强度超声聚焦刀联合FOLFOX4方案治疗晚期胰腺癌的疗效较好，不良反应可耐受，值得临床应用。%Objective To evaluate the efficacy and safety of high intensity focused ultrasound (HIFU) combined with FOLFOX4 in the treatment of advanced pancreatic carcinoma. Method Sixty patients with advanced pancreatic carcino-ma were enrolled in this study, and were divied into study group (n=32) or control group (n=28) according to treatment modality, FOLFOX4 was administered in both groups, while the study group was given additional HIFU. The efficacy, ad-verse reactions, pain relief and progression-free survival (PFS) were compared between the two groups. Result The re-sponse rate (RR) of the study group and control group was 28.1%and 7.1%, the disease control rate (DCR) was 71.9%and 35.7%, and both were significantly higher in the study group (P<0.05). The study group had a pain relief rate of 53.1%(17/32), which was higher than that of the control group at 21.4%(6/28), with significant difference observed (P<0.05). The median PFS of the study group was 6.1 months, longer than that in the control group at 2.8 months, and the dif-ference was statistically significant (P<0.05). The most common adverse reactions were hematological toxicity, nausea and vomiting, and neurotoxicity, of which the incidences were similar between the two groups (P>0.05). Conclusion High intensity focused ultrasound combined with FOLFOX4 is quite effectiveand well tolerated in the treatment of ad-vanced pancreatic carcinoma, and is worthy of clinical application.
展开▼
